CureVac
CVAC
CVAC was delisted on the 5th of January, 2026.
90 hedge funds and large institutions have $55M invested in CureVac in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 23 reducing their positions, and 15 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 23
4% more call options, than puts
Call options by funds: $1M | Put options by funds: $968K
0% more funds holding
Funds holding: 90 → 90 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
2.08% less ownership
Funds ownership: 9.92% → 7.83% (-2.1%)
41% less capital invested
Capital invested by funds: $93.4M → $55M (-$38.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$2.01M |
| 2 |
Morgan Stanley
New York
|
+$1.1M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$827K |
| 4 |
D.E. Shaw & Co
New York
|
+$766K |
| 5 |
BlackRock
New York
|
+$594K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.79M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$6.87M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.73M |
| 4 |
Walleye Capital
New York
|
-$2.65M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.16M |
CVAC Hedge Fund Activity: Q1 2024 in Review
90 institutional investors reported a position in CureVac (CVAC) for Q1 2024, worth a combined $55M — down 41% from $93.4M a quarter earlier.
Fund positioning in CVAC was balanced in Q1 2024: 15 funds opened new positions, 15 closed out, 34 added to existing stakes and 23 trimmed.
The largest buyer was UBS Group, adding an estimated $2.01M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $9.79M sold.
- 90 institutional investors held CureVac (CVAC) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $55M of CureVac stock for Q1 2024, down 41% quarter-over-quarter.
- 15 funds opened new CureVac positions in Q1 2024 and 15 closed out, a net change of 0 holders.
- The largest CureVac buyer in Q1 2024 was UBS Group, an estimated $2.01M added.
- The largest CureVac seller in Q1 2024 was T. Rowe Price Associates, an estimated $9.79M sold.
Based on aggregated 13F filings for Q1 2024.